Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06933095 · ClinicalTrials.gov registry record · NA

Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia

A NA study of Cognitive Decline and Memory Decline, sponsored by University of Cincinnati.

Recruiting
Registry status
NA
Development phase
153
Enrollment target
1
Study location

NCT06933095: Recruiting NA study of Cognitive Decline and Memory Decline, sponsored by University of Cincinnati.

NCT06933095 is a NA study of Cognitive Decline and Memory Decline that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 153 participants, below the 1,147-participant average among 61 other Cognitive Decline trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06933095, a NA study of Cognitive Decline and Memory Decline, is actively recruiting participants, sponsored by University of Cincinnati.

RECRUITING
Registry status
NA
Development phase
153 participants
Enrollment target
1
Study location

Study Summary

The purpose of this placebo-controlled trial is to compare the effects of 24-weeks supplementation with LPC-DHA and TAG-DHA on cerebrospinal fluid and blood DHA levels, as well as biomarkers of central neurodegenerative and neurotrophic activity, in elderly adults experiencing early signs of cognitive/memory decline including those with mild cognitive impairment (MCI). Extant evidence supports our overarching hypothesis that LPC-DHA supplementation will be more effective than TAG-DHA for increasing central (CSF) DHA levels and improving biomarker profiles in elderly adults. To assess this hypothesis, the following aims are proposed: SPECIFIC AIM 1: To compare the effects of LPC-DHA and TAG-DHA supplementation on peripheral and CSF DHA levels in elderly adults experiencing early signs of cognitive/memory decline. SPECIFIC AIM 2: To compare the effects of LPC-DHA and TAG-DHA supplementation on neurotrophic and neurodegenerative biomarkers. Secondary Aim: To investigate whether changes in CSF DHA levels correlate with changes in objective measures of executive functioning and episodic memory performance.

Primary Outcome

Baseline-Endpoint change in CSF docosahexaenoic acid (DHA) composition (g/100 g).

Conditions Studied

Cognitive Decline Memory Decline Eldery People DHA CNS Delivery

Interventions

  • DIETARY_SUPPLEMENT LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)

Study Locations (1)

Ohio

  • University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience - Cincinnati

Trial Details

FieldValue
Enrollment Target 153 participants
Start Date 2024-09-15
Est. Completion 2029-09-15
Phase NA
University of Cincinnati

245 total trials

What NCT06933095 shows while recruiting

NCT06933095 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 1,147-participant average among 61 other Cognitive Decline trials with a reported enrollment target (87% lower).

The record links to 4 conditions, with Cognitive Decline appearing as the primary indexed condition, and to 1 intervention - of which LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta) is the first listed.

NCT06933095 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06933095 about?

NCT06933095 is a clinical study titled "Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia". The purpose of this placebo-controlled trial is to compare the effects of 24-weeks supplementation with LPC-DHA and TAG-DHA on cerebrospinal fluid and blood DHA levels, as well as biomarkers of central neurodegenerative and neurotrophic activity, in elderly adults experiencing early signs of cogniti...

What is the current status of trial NCT06933095?

This trial is currently recruiting. It is a NA study. The enrollment target is 153 participants. The study started on 2024-09-15. Estimated completion is 2029-09-15.

What conditions does trial NCT06933095 study?

This clinical trial studies the following conditions: Cognitive Decline, Memory Decline, Eldery People, DHA CNS Delivery.

What interventions are being tested in trial NCT06933095?

The interventions under investigation include: LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06933095?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06933095 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cognitive Decline

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06933095's enrollment target sits among peer trials

153 30th of 61 higher than 32 of 61 other Cognitive Decline trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cognitive Decline trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05283265 · 153 participants · NA

    Neurophysiological Mechanisms of Language Comprehension

  • NCT05554393 · 153 participants · Phase 2

    Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • NCT05584501 · 153 participants · NA

    ETE Interventions in the Dental Setting

  • NCT05714839 · 153 participants · Phase 1

    A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06933095

Source: ClinicalTrials.gov NCT06933095, the US trial registry maintained by the National Library of Medicine. NCT06933095 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.